AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00560573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75\* mg/m2 or 80\* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~\* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine
Study NCT00560573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
Study NCT00560573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
Study NCT04070833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D placebo
Study NCT04070833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT04070833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT03373175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basal record
Description: Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
Study NCT03373175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 10 record
Description: PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
Study NCT03099265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant mFOLFIRINOX
Description: Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
Study NCT03099265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
Study NCT03373175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 15 record
Description: PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
Study NCT03269565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody
Study NCT03373175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS 20 record
Description: PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
Study NCT03125369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy + duodeno-jejunal bypass
Study NCT03125369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-Y gastric bypass
Study NCT03863210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk
Description: All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits.
Study NCT04379167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
Study NCT03512106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Chinese traditional acupuncture
Study NCT03512106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Chinese traditional acupuncture
Study NCT05446116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial splenic artery embolization
Description: embolization of the splenic artery for the treatment of hypersplenism
Study NCT01935492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Description: 1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine.
Study NCT01935492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Description: Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line.
Study NCT04279002 — intervention group
Intervention type: OTHER
Intervention: Brief 15-question questionnaire
Description: Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
Study NCT01339273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Transversus Abdominis Plane (TAP) bock
Description: Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
Study NCT01339273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthetic infiltration of laparoscopic port sites
Description: Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
Study NCT02978729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-way videoconference remote genetic counseling
Study NCT02978729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone remote genetic counseling
Study NCT03076307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Procedural Motor Skills with mirror-drawing of figures
Description: Evaluation of error rate and speed for completion of a procedural motor task
Study NCT03076307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procedural Motor Skills with mirror-drawing of figures
Description: Evaluation of error rate and speed for completion of a procedural motor task
Study NCT01366846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avoidance of peanut
Description: All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
Study NCT03752424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver nanoparticles
Description: The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
Study NCT03752424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical approved anti-microbial gel
Description: The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Study NCT00952432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Carbamazepine 200mg, 1/2 tablet, TID for 1 month
Study NCT00952432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture
Study NCT02140801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Plain, round, yellow, filmcoated tablet, 90 mg
Study NCT01956110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta (FE 999049)
Study NCT01956110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa (GONAL-F)
Study NCT00460941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc weekly
Study NCT00460941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20mg
Description: sc weekly
Study NCT00460941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20mg-30mg
Description: sc weekly
Study NCT00460941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20mg-40mg
Description: sc weekly
Study NCT03182348 — intervention group
Intervention type: PROCEDURE
Intervention: Optical coherence tomography
Description: As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
Study NCT00846118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: 1-4mg/day
Study NCT03085329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seattle-PAP
Description: Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
Study NCT03085329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional bubble nasal CPAP
Description: Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
Study NCT00742313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FloSeal Matrix
Description: 10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
Study NCT01660711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: 2400 mg/m2 by continuous intravenous infusion over 46 hours
Study NCT01660711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 by IV infusion over 2 hours
Study NCT01660711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
Study NCT02140801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
Study NCT01660711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² IV infusion on Day 1 over 2 hours
Study NCT04300296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg Q4W
Description: secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
Study NCT04300296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg Q2W
Description: secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
Study NCT04300296 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered via a pre-filled syringe
Study NCT01891136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut protein
Description: Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
Study NCT02364882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Study NCT02364882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Study NCT02871921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversational Engagement
Description: Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
Study NCT02365701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motilitone 30mg
Description: 30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
Study NCT02365701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
Study NCT03677973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AB680
Description: AB680 is a Cluster of Differentiation (CD)73 Inhibitor
Study NCT03677973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT03140813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (High-Dose)
Description: 15mg PO BID
Study NCT03140813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (Low-Dose)
Description: 5mg PO BID
Study NCT03140813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
Study NCT02378844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore®-R
Description: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
Study NCT02378844 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore®-R Sham
Description: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
Study NCT03431116 — intervention group
Intervention type: RADIATION
Intervention: ultrasound
Description: to detect the placental site
Study NCT01919424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma
Study NCT01919424 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trudell AeroEclipse*II BAN nebulizer
Description: Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
Study NCT01919424 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The English-Wright nebulizer
Description: Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada
Study NCT03509129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TECH (Technology)
Description: Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR
Study NCT03509129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TECH+COMP (Technology + Competition)
Description: Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR
Study NCT00463060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate (Sutent)
Description: Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
Study NCT00463060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
Study NCT00701129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alglucosidase Alfa
Description: Administered as IV infusion.
Study NCT00701129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered subcutaneously.
Study NCT00701129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered as IV infusion.
Study NCT00401011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Study NCT01392469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Film coated tablets, oral administration
Study NCT01392469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral Administration
Study NCT00401011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Study NCT00401011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
Study NCT02412631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin
Description: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
Study NCT01392469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Oral Administration
Study NCT02412631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Chantix is an FDA approved medication for smoking cessation
Study NCT02412631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Chantix is an FDA approved medication for smoking cessation
Study NCT02412631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for lorcaserin